Taken together, although PpargΔHep did not reduce the levels of plasma ALT nor steatosis, these data indicated that hepatocyte PPARγ and CD36 expressions could contribute to the upregulation of genes related to the progression of NASH. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.